Get the Stockscreener App
6.36
5.22%
-0.35
After Hours:
6.24
-0.12
-1.89%
Cingulate Inc stock is traded at $6.36, with a volume of 531.37K.
It is down -5.22% in the last 24 hours and down -6.61% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
See More
Previous Close:
$6.71
Open:
$6.76
24h Volume:
531.37K
Relative Volume:
1.24
Market Cap:
$73.96M
Revenue:
-
Net Income/Loss:
$-22.21M
P/E Ratio:
-1.4619
EPS:
-4.3505
Net Cash Flow:
$-17.41M
1W Performance:
-20.90%
1M Performance:
-6.61%
6M Performance:
+67.81%
1Y Performance:
+59.00%
1-Day Range:
$6.20
$6.89
1-Week Range:
$6.20
$8.20
52-Week Range:
$3.20
$11.89
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
6.36 | 78.03M | 0 | -22.21M | -17.41M | -4.3505 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
[EFFECT] Cingulate Inc. SEC Fi... | CING SEC FilingForm EFFECT - Stock Titan
Can Cingulate Inc Equity Warrant sustain earnings growthWeekly Trade Review & Trade Opportunity Analysis - baoquankhu1.vn
Cingulate Inc. Enters ATM Sales Agreement with A.G.P./Alliance Global Partners for Common Stock Offering – March 2026 - Minichart
Cingulate Announces ATM Equity Program and Share Issuance - TipRanks
Cingulate Inc has submitted a prospectus supplement to the U.S. Securities and Exchange Commission, planning to conduct a market offering and sell common shares in phases for a total amount of up to 100 million dollars. - Bitget
Cingulate (NASDAQ: CING) adds $100M ATM share sale capacity - Stock Titan
Cingulate Inc. (NASDAQ: CING) launches up to $100M ATM sales program - Stock Titan
Cingulate’s ADHD Drug Is Near An FDA Verdict - Finimize
Roth Capital Lowers Price Target for Cingulate (CING) to $14, Ma - GuruFocus
Roth Mkm Cuts Cingulate (NASDAQ:CING) Price Target to $14.00 - MarketBeat
Cingulate (NASDAQ: CING) files S-3/A amendment adding KPMG consent - Stock Titan
If You Invested $1,000 in Cingulate Inc (CING) - Stock Titan
History Review: Is Cingulate Inc likely to announce a buyback2026 Fundamental Recap & Low Volatility Stock Recommendations - baoquankhu1.vn
Cingulate Stock Snaps 2-Day Losing Streak As Roth Hikes Target On ADHD Drug Review; Retail Bets On Buyout Potential - MSN
What's going on with Cingulate stock today? - MSN
Cingulate stock jumps overnight: US Patent Office clears ADHD drug filing ahead of May FDA catalyst - MSN
Stock Report: How cyclical is Cingulate Inc Equity Warrants revenue stream2026 Valuation Update & Long Hold Capital Preservation Plans - baoquankhu1.vn
CING: Laying the Foundation for 1H:27 Launch - Research Tree
What's Going On With Cingulate Stock Today? - Benzinga
3.5M-share resale registration by Cingulate (NASDAQ: CING) under Lincoln Park deal - Stock Titan
Cingulate (NASDAQ:CING) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS - MarketBeat
Cingulate (CING) Expected to Announce Earnings on Thursday - MarketBeat
Cingulate Reports 2025 Financial Results, Advances CTx-1301 ADHD Drug with New Patents and NDA Progress - Minichart
Cingulate Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights - Bitget
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Cingulate Inc. Advances Precision Timed Release ADHD and Anxiety Treatments with Innovative Drug Delivery Platform – 2025 Annual Report Highlights - Minichart
Cingulate (CING) outlines CTx-1301 FDA review, ADHD market and PTR pipeline - Stock Titan
Cingulate 10-K: $0 Revenue, $(22.45)M Net Loss - TradingView
PolyPid Approaches NDA Submission as New Medicare Model Creates Strong Incentives for SSI Prevention - Benzinga
CING: 2025 net loss widened to $22.4M as CTx-1301 advanced toward FDA review and $12M was raised - TradingView
CING: NDA for CTx-1301 accepted, $12M raised, and cash runway extends into late Q4 2026 - TradingView
CING: 2025 net loss widened to $22.4M; cash runway into late 2026, pending CTx-1301 FDA approval - TradingView
Patent wins and $12M PIPE support Cingulate (NASDAQ: CING) - Stock Titan
Cingulate Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Gains Report: How is Cingulate Inc managing supply chain issues2026 Macro Moves & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Why did Cingulate stock skyrocket today? - CryptoRank
Cingulate Stock Jumps Overnight: US Patent Office Clears ADHD Drug Filing Ahead Of May FDA Catalyst - Asianet Newsable
Cingulate (CING) CEO gets 6,862-share bonus grant, 2,959 withheld for tax - Stock Titan
Cingulate (CING) EVP awarded 4,526 shares; 1,828 withheld for taxes - Stock Titan
Cingulate (NASDAQ:CING) Trading Up 6.5%Here's What Happened - MarketBeat
How strong is Cingulate Inc. stock revenue growthPortfolio Gains Summary & Risk Controlled Stock Alerts - Naître et grandir
EPS Watch: Is Cingulate Inc currently under institutional pressureMarket Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
Fundamentals Check: Is Cingulate Inc likely to announce a buybackJuly 2025 Reactions & Consistent Growth Equity Picks - baoquankhu1.vn
Retail Trends: How cyclical is Cingulate Inc Equity Warrants revenue streamTrade Risk Report & Expert Verified Movement Alerts - baoquankhu1.vn
Can Cingulate Inc. stock rebound after recent weaknessNew Guidance & Free Technical Confirmation Trade Alerts - Naître et grandir
CING|Cingulate Inc|Price:6.430|Chg%:-0.13 - TradingKey
Cingulate (NASDAQ: CING) vote on 19% share issuance and warrants - Stock Titan
Pullback Watch: Is Cingulate Inc Equity Warrant a turnaround storyJuly 2025 Catalysts & Long-Term Growth Plans - baoquankhu1.vn
Risk Hedge: Can Cingulate Inc Equity Warrant maintain its current growth ratePrice Action & Daily Volume Surge Signals - baoquankhu1.vn
CING Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):